Journal
JOURNAL OF IMMUNOLOGY
Volume 174, Issue 6, Pages 3264-3272Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.174.6.3264
Keywords
-
Categories
Funding
- NIAID NIH HHS [R01 AI31105] Funding Source: Medline
Ask authors/readers for more resources
C3dg is a cleavage product of the C3 component of complement that can facilitate the coligation of the complement receptor 2 (CR2/CD21) with the BCR via C3dg/Ag complexes. This interaction can greatly amplify BCR-mediated signaling events and acts to lower the threshold for B cell activation. Although previous studies have used anti-CR2 Abs, or used chimeric Ags in the context of BCR transgenic mice as surrogate CM-containing ligands, we have used a physiological form of C3d to study signaling in B cells from wild-type C57BL/6 mice. We find that while CR2-enhanced BCR signaling causes intracellular Ca2+ mobilization and total pTyr phosphorylation of an intensity comparable to optimal BCR ligation using anti-IgM Abs, it does so with limited activation of inhibitory effectors (such as CD22, Src homology region 2 domain containing phosphatase 1, and SHIP-1) and without substantial receptor cross-linking. In summary, we demonstrate that CR2-enhanced BCR signaling may proceed not only through the previously described amplification of positive signaling pathways, but is potentially augmented by a lack of normal inhibitory/ feedback signaling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available